<p>Benitec Biopharma Limited (NASDAQ:BNTC - 获取免费报告) 在目前覆盖该股票的八位分析师中获得了 “适度买入” 的平均评级，Marketbeat.com 报道称。一位股票研究分析师给予该股票卖出建议，一位给予持有建议，六位则对该公司发布了买入建议。在过去一年中，发布报告的分析师对该股票的平均十二个月目标价格为 26.25 美元。</p>
<p>BNTC 最近成为几份分析师报告的主题。Citizens Jmp 将 Benitec Biopharma 的目标价格从 20.00 美元上调至 22.00 美元，并在 11 月 4 日（星期二）的报告中给予该股票 “市场表现优于大盘” 的评级。Oppenheimer 在 9 月 16 日（星期二）的报告中重申了 “表现优于大盘” 的评级，并将 Benitec Biopharma 的目标价格设定为 29.00 美元（之前为 35.00 美元）。Wall Street Zen 在 11 月 22 日（星期六）的研究报告中将 Benitec Biopharma 的评级从 “卖出” 上调至 “持有”。HC Wainwright 在 11 月 24 日（星期一）的研究报告中将 Benitec Biopharma 的目标价格设定为 32.00 美元，并给予该公司 “买入” 评级。最后，Weiss Ratings 在 10 月 8 日（星期三）的研究报告中重申了对 Benitec Biopharma 的 “卖出（d-）” 评级。</p>
<p>获取 <strong>Benitec Biopharma</strong> 的提醒：</p>
<p><strong>阅读我们最新的 BNTC 股票报告</strong></p>
<h2>Benitec Biopharma 的内部买卖</h2>
<p>在相关消息中，董事 Suvretta Capital Management, L 于 11 月 7 日（星期五）购买了 1,481,481 股该公司的股票。每股购买价格为 13.50 美元，总交易额为 19,999,993.50 美元。收购完成后，该董事直接持有该公司 9,538,175 股股票，价值 128,765,362.50 美元。此次交易使其持股增加了 18.39%。该交易已在证券交易委员会的备案中披露，相关信息可通过 SEC 网站访问。内部人士持有该公司 4.80% 的股份。</p>
<h2>机构资金流入和流出</h2>
<p>对该公司的对冲基金最近调整了持股。Ameriprise Financial Inc. 在第三季度将其在 Benitec Biopharma 的持股增加了 40.5%。Ameriprise Financial Inc. 目前持有 154,414 股该生物技术公司的股票，价值 2,166,000 美元，在上个季度又购买了 44,489 股。瑞银集团（UBS Group AG）在第三季度将其在 Benitec Biopharma 的持股增加了 458.8%。瑞银集团目前持有 99,941 股该生物技术公司的股票，价值 1,402,000 美元，在上个季度又购买了 82,057 股。法国巴黎银行金融市场（BNP Paribas Financial Markets）在第三季度将其在 Benitec Biopharma 的持股增加了 44.5%。法国巴黎银行金融市场目前持有 2,937 股该生物技术公司的股票，价值 41,000 美元，在上个季度又购买了 904 股。拉塞尔投资集团（Russell Investments Group Ltd.）在第三季度获得了 Benitec Biopharma 的新股份，价值约 79,000 美元。最后，先锋集团（Vanguard Group Inc.）在第三季度将其在 Benitec Biopharma 的持股增加了 2.4%。先锋集团目前持有 992,114 股该生物技术公司的股票，价值 13,919,000 美元，在上个季度又购买了 22,948 股。52.19% 的股票由机构投资者和对冲基金持有。</p>
<h2>Benitec Biopharma 价格表现</h2>
<p>BNTC 的股票在周一开盘价为 11.98 美元。Benitec Biopharma 的一年低点为 9.70 美元，一年高点为 17.15 美元。该公司的 50 日简单移动平均线为 14.11 美元，200 日简单移动平均线为 13.62 美元。该股票的市值为 4.0564 亿美元，市盈率为-9.90，贝塔值为 0.20。</p>
<p>Benitec Biopharma (NASDAQ:BNTC - 获取免费报告) 最近于 11 月 14 日（星期五）发布了其财报。这家生物技术公司报告的每股收益为（0.22 美元），超过分析师一致预期的（0.35 美元）0.13 美元。平均而言，卖方分析师预计 Benitec Biopharma 在当前年度的每股收益将为-1.48 美元。</p>
<h2>关于 Benitec Biopharma</h2>
<p>（获取免费报告）</p>
<p>Benitec Biopharma Inc. 是一家临床阶段的生物技术公司，专注于新型基因药物的开发。该公司开发基于 DNA 导向的 RNA 干扰治疗，用于治疗慢性和危及生命的人类疾病。它正在开发 BB-301，一种用于治疗眼咽肌肉萎缩的腺病毒相关基因治疗剂。</p>
<h2>推荐故事</h2>
<ul>
<li>我们更看好的五只股票，胜过 Benitec Biopharma</li>
<li>股票交易：相对强弱指数及其用途</li>
<li>Dave &amp; Buster’s 的反转在双底突破后进入了游戏</li>
<li>债券市场假期是什么？如何投资和交易</li>
<li>3 只在 10 年期国债利率上升时值得购买的金融股票</li>
<li>股票拆分意味着什么？</li>
<li>迪士尼的 10 亿美元交易将其魔力带入 OpenAI</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Qk5UQw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Qk5UQw"/></p>
<p><em>此即时新闻提醒由叙述科学技术和来自 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1000 美元在 Benitec Biopharma 吗？</h2>
<p>在你考虑 Benitec Biopharma 之前，你会想听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Benitec Biopharma 并不在名单上。</p>
<p>虽然 Benitec Biopharma 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

BNTC

<p>Benitec Biopharma Limited（纳斯达克代码：BNTC - 获取免费报告）在目前覆盖该股票的八位分析师中获得了 “适度买入” 的平均评级，Marketbeat.com 报道</p>

<p>Benitec Biopharma Limited (NASDAQ:BNTC - Get Free Report) has earned an average rating of &#34;Moderate Buy&#34; from the eight analysts that are currently covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and six have issued a buy recommendation on the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $26.25.</p>
<div class="lb-trans"><p>Benitec Biopharma Limited (NASDAQ:BNTC - 获取免费报告) 在目前覆盖该股票的八位分析师中获得了 “适度买入” 的平均评级，Marketbeat.com 报道称。一位股票研究分析师给予该股票卖出建议，一位给予持有建议，六位则对该公司发布了买入建议。在过去一年中，发布报告的分析师对该股票的平均十二个月目标价格为 26.25 美元。</p>
</div><p>BNTC has been the topic of several recent analyst reports. Citizens Jmp increased their price target on Benitec Biopharma from $20.00 to $22.00 and gave the stock a &#34;market outperform&#34; rating in a report on Tuesday, November 4th. Oppenheimer restated an &#34;outperform&#34; rating and set a $29.00 target price (down previously from $35.00) on shares of Benitec Biopharma in a report on Tuesday, September 16th. Wall Street Zen upgraded Benitec Biopharma from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a research note on Saturday, November 22nd. HC Wainwright set a $32.00 price target on shares of Benitec Biopharma and gave the company a &#34;buy&#34; rating in a research report on Monday, November 24th. Finally, Weiss Ratings reaffirmed a &#34;sell (d-)&#34; rating on shares of Benitec Biopharma in a research report on Wednesday, October 8th.</p>
<div class="lb-trans"><p>BNTC 最近成为几份分析师报告的主题。Citizens Jmp 将 Benitec Biopharma 的目标价格从 20.00 美元上调至 22.00 美元，并在 11 月 4 日（星期二）的报告中给予该股票 “市场表现优于大盘” 的评级。Oppenheimer 在 9 月 16 日（星期二）的报告中重申了 “表现优于大盘” 的评级，并将 Benitec Biopharma 的目标价格设定为 29.00 美元（之前为 35.00 美元）。Wall Street Zen 在 11 月 22 日（星期六）的研究报告中将 Benitec Biopharma 的评级从 “卖出” 上调至 “持有”。HC Wainwright 在 11 月 24 日（星期一）的研究报告中将 Benitec Biopharma 的目标价格设定为 32.00 美元，并给予该公司 “买入” 评级。最后，Weiss Ratings 在 10 月 8 日（星期三）的研究报告中重申了对 Benitec Biopharma 的 “卖出（d-）” 评级。</p>
</div><p>Get <strong>Benitec Biopharma</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Benitec Biopharma</strong> 的提醒：</p>
</div><p><strong>Read Our Latest Stock Report on BNTC</strong></p>
<div class="lb-trans"><p><strong>阅读我们最新的 BNTC 股票报告</strong></p>
</div><h2>Insider Buying and Selling at Benitec Biopharma</h2>
<div class="lb-trans"><h2>Benitec Biopharma 的内部买卖</h2>
</div><p>In related news, Director Suvretta Capital Management, L acquired 1,481,481 shares of the business's stock in a transaction dated Friday, November 7th. The shares were purchased at an average price of $13.50 per share, for a total transaction of $19,999,993.50. Following the completion of the acquisition, the director directly owned 9,538,175 shares in the company, valued at $128,765,362.50. The trade was a 18.39% increase in their position. The transaction was disclosed in a filing with the Securities &amp; Exchange Commission, which can be accessed through the SEC website. Insiders own 4.80% of the company's stock.</p>
<div class="lb-trans"><p>在相关消息中，董事 Suvretta Capital Management, L 于 11 月 7 日（星期五）购买了 1,481,481 股该公司的股票。每股购买价格为 13.50 美元，总交易额为 19,999,993.50 美元。收购完成后，该董事直接持有该公司 9,538,175 股股票，价值 128,765,362.50 美元。此次交易使其持股增加了 18.39%。该交易已在证券交易委员会的备案中披露，相关信息可通过 SEC 网站访问。内部人士持有该公司 4.80% 的股份。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入和流出</h2>
</div><p>Hedge funds have recently modified their holdings of the company. Ameriprise Financial Inc. raised its position in Benitec Biopharma by 40.5% during the 3rd quarter. Ameriprise Financial Inc. now owns 154,414 shares of the biotechnology company's stock worth $2,166,000 after buying an additional 44,489 shares during the last quarter. UBS Group AG raised its position in shares of Benitec Biopharma by 458.8% during the 3rd quarter. UBS Group AG now owns 99,941 shares of the biotechnology company's stock worth $1,402,000 after purchasing an additional 82,057 shares during the last quarter. BNP Paribas Financial Markets lifted its stake in Benitec Biopharma by 44.5% in the 3rd quarter. BNP Paribas Financial Markets now owns 2,937 shares of the biotechnology company's stock valued at $41,000 after buying an additional 904 shares in the last quarter. Russell Investments Group Ltd. acquired a new stake in Benitec Biopharma in the 3rd quarter worth about $79,000. Finally, Vanguard Group Inc. increased its stake in Benitec Biopharma by 2.4% during the 3rd quarter. Vanguard Group Inc. now owns 992,114 shares of the biotechnology company's stock worth $13,919,000 after buying an additional 22,948 shares in the last quarter. 52.19% of the stock is owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>对该公司的对冲基金最近调整了持股。Ameriprise Financial Inc. 在第三季度将其在 Benitec Biopharma 的持股增加了 40.5%。Ameriprise Financial Inc. 目前持有 154,414 股该生物技术公司的股票，价值 2,166,000 美元，在上个季度又购买了 44,489 股。瑞银集团（UBS Group AG）在第三季度将其在 Benitec Biopharma 的持股增加了 458.8%。瑞银集团目前持有 99,941 股该生物技术公司的股票，价值 1,402,000 美元，在上个季度又购买了 82,057 股。法国巴黎银行金融市场（BNP Paribas Financial Markets）在第三季度将其在 Benitec Biopharma 的持股增加了 44.5%。法国巴黎银行金融市场目前持有 2,937 股该生物技术公司的股票，价值 41,000 美元，在上个季度又购买了 904 股。拉塞尔投资集团（Russell Investments Group Ltd.）在第三季度获得了 Benitec Biopharma 的新股份，价值约 79,000 美元。最后，先锋集团（Vanguard Group Inc.）在第三季度将其在 Benitec Biopharma 的持股增加了 2.4%。先锋集团目前持有 992,114 股该生物技术公司的股票，价值 13,919,000 美元，在上个季度又购买了 22,948 股。52.19% 的股票由机构投资者和对冲基金持有。</p>
</div><h2>Benitec Biopharma Price Performance</h2>
<div class="lb-trans"><h2>Benitec Biopharma 价格表现</h2>
</div><p>Shares of BNTC opened at $11.98 on Monday. Benitec Biopharma has a 1 year low of $9.70 and a 1 year high of $17.15. The business's 50 day simple moving average is $14.11 and its 200-day simple moving average is $13.62. The stock has a market capitalization of $405.64 million, a price-to-earnings ratio of -9.90 and a beta of 0.20.</p>
<div class="lb-trans"><p>BNTC 的股票在周一开盘价为 11.98 美元。Benitec Biopharma 的一年低点为 9.70 美元，一年高点为 17.15 美元。该公司的 50 日简单移动平均线为 14.11 美元，200 日简单移动平均线为 13.62 美元。该股票的市值为 4.0564 亿美元，市盈率为-9.90，贝塔值为 0.20。</p>
</div><p>Benitec Biopharma (NASDAQ:BNTC - Get Free Report) last posted its earnings results on Friday, November 14th. The biotechnology company reported ($0.22) earnings per share for the quarter, topping analysts' consensus estimates of ($0.35) by $0.13. On average, sell-side analysts expect that Benitec Biopharma will post -1.48 earnings per share for the current year.</p>
<div class="lb-trans"><p>Benitec Biopharma (NASDAQ:BNTC - 获取免费报告) 最近于 11 月 14 日（星期五）发布了其财报。这家生物技术公司报告的每股收益为（0.22 美元），超过分析师一致预期的（0.35 美元）0.13 美元。平均而言，卖方分析师预计 Benitec Biopharma 在当前年度的每股收益将为-1.48 美元。</p>
</div><h2>About Benitec Biopharma</h2>
<div class="lb-trans"><h2>关于 Benitec Biopharma</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Benitec Biopharma Inc, a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy.</p>
<div class="lb-trans"><p>Benitec Biopharma Inc. 是一家临床阶段的生物技术公司，专注于新型基因药物的开发。该公司开发基于 DNA 导向的 RNA 干扰治疗，用于治疗慢性和危及生命的人类疾病。它正在开发 BB-301，一种用于治疗眼咽肌肉萎缩的腺病毒相关基因治疗剂。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推荐故事</h2>
</div><ul>
<li>Five stocks we like better than Benitec Biopharma</li>
<li>Trading Stocks: RSI and Why it's Useful</li>
<li>Dave &amp; Buster’s Reversal Is in PLAY After Double-Bottom Breakout</li>
<li>What is a Bond Market Holiday? How to Invest and Trade</li>
<li>3 Finance Stocks to Buy on Rising 10-Year Treasury Rates</li>
<li>What Does a Stock Split Mean?</li>
<li>Disney's $1 Billion Deal Brings Its Magic to OpenAI</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，胜过 Benitec Biopharma</li>
<li>股票交易：相对强弱指数及其用途</li>
<li>Dave &amp; Buster’s 的反转在双底突破后进入了游戏</li>
<li>债券市场假期是什么？如何投资和交易</li>
<li>3 只在 10 年期国债利率上升时值得购买的金融股票</li>
<li>股票拆分意味着什么？</li>
<li>迪士尼的 10 亿美元交易将其魔力带入 OpenAI</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Qk5UQw" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=BNTC"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和来自 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Benitec Biopharma Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在 Benitec Biopharma 吗？</h2>
</div><p>Before you consider Benitec Biopharma, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Benitec Biopharma 之前，你会想听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Benitec Biopharma wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Benitec Biopharma 并不在名单上。</p>
</div><p>While Benitec Biopharma currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Benitec Biopharma 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Benitec Biopharma Limited（纳斯达克代码：BNTC）被券商给予 “适度买入” 的平均评级